Strive Pharmacy to Launch Compounded Wegovy Pill Following Hims & Hers Withdrawal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy HIMS?
Source: seekingalpha
- Market Response: Strive Pharmacy plans to introduce a compounded version of Novo Nordisk's newly launched oral obesity therapy, Wegovy, following Hims & Hers' withdrawal last month, demonstrating sensitivity to market demand.
- Compliance Challenges: Hims & Hers halted sales shortly after launching a low-cost compounded Wegovy due to regulatory scrutiny and a lawsuit from Novo Nordisk, resulting in the destruction of manufactured pills, highlighting the complexities of market competition.
- Operational Adjustments: Strive's Chief Compliance Officer noted that while a timeline for reintroduction is not set, the company has established operations to meet Hims & Hers' demand forecasts for the semaglutide pill, showcasing its ability to adapt to market changes.
- Strategic Reset: Following Hims & Hers' product withdrawal, Strive Pharmacy must adjust its operational strategy to fit the new market environment, a process that could impact not only its short-term business but also its long-term market positioning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 19.840
Low
16.50
Averages
32.95
High
60.00
Current: 19.840
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Stock Experiences Increased Volatility
- Market Volatility: Hims & Hers stock has exhibited significant volatility in recent months, reflecting market uncertainty regarding its future performance, which could impact investor confidence and capital inflows.
- Price Fluctuation: As of the afternoon of March 30, 2026, Hims & Hers stock was priced at $3.45, indicating instability in the market that may increase investment risks in the short term.
- Investor Attention: Due to the high volatility of the stock, investors may need to reassess their investment strategies to cope with potential price swings and market risks, thereby affecting the overall performance of their portfolios.
- Market Sentiment: The volatility of Hims & Hers stock may trigger changes in market sentiment, leading investors to develop varying perspectives on the company's future prospects, which could influence its market performance.
See More
Hims & Hers Stock Volatility Analysis
- Market Volatility: Hims & Hers (NYSE: HIMS) has recently emerged as one of the most volatile stocks in the market, reflecting investor uncertainty about its future performance, which could impact its short-term stock price.
- Lack of Investment Recommendations: The Motley Fool Stock Advisor analyst team has indicated that Hims & Hers is not among the current top 10 recommended stocks, suggesting a cautious market sentiment regarding its growth potential, which may lead investors to reassess its investment value.
- Historical Return Comparison: Compared to previously recommended stocks like Netflix and Nvidia, which yielded returns of 515,294% and 1,077,442% respectively, Hims & Hers has not demonstrated similar appeal, indicating a lack of confidence in the stock.
- Investor Community Engagement: The Motley Fool encourages investors to join its community to share insights, and while Hims & Hers has not made the recommendation list, it still maintains a degree of attention among investors, potentially influencing future market dynamics.
See More
Hims & Hers Health Faces Legal Investigation Over Securities Violations
- Legal Investigation Launched: The Schall Law Firm is investigating Hims & Hers Health for potential securities law violations, focusing on whether the company made false or misleading statements that could harm investors' interests.
- FDA Statement Impact: The FDA announced its intent to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, directly affecting Hims & Hers' market operations and potentially leading to stricter regulations.
- Increased Litigation Risk: Hims & Hers is also facing a lawsuit from Novo Nordisk seeking to bar the sale of compounded weight loss drugs, which will further escalate the company's legal risks and could impact its market share.
- Significant Stock Decline: Following these developments, Hims & Hers' shares fell by over 17.8% during afternoon trading on February 9, 2026, reflecting market concerns about the company's future prospects and potentially undermining investor confidence.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
FDA Moves to Lift Restrictions on Peptides, Boosting Hims & Hers Shares
- Stock Surge: Hims & Hers Health Inc. (HIMS) shares surged nearly 6% in Tuesday morning trading, primarily driven by the FDA's plan to lift restrictions on peptide drugs, reflecting market optimism about the company's growth prospects.
- Policy Shift: According to a report by The New York Times, the FDA is considering allowing compounding pharmacies to manufacture over a dozen injectable peptides that were previously banned due to safety risks, which will create new market opportunities for companies like HIMS.
- Market Impact: This policy reversal will end a 2023 ban on 14 peptides, meaning HIMS can re-enter this potentially lucrative market, thereby enhancing its competitiveness in the compounded medication sector.
- Industry Outlook: With the FDA's decision, HIMS is poised to expand its product line to meet the growing customer demand, further solidifying its market position in the health tech industry.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
Hims & Hers Stock Experiences Increased Volatility
- Market Volatility: Hims & Hers stock has exhibited significant volatility in recent months, reflecting market uncertainty regarding its future performance, which could impact investor confidence and capital inflows.
- Price Fluctuation: As of the afternoon of March 30, 2026, Hims & Hers stock was priced at $3.45, indicating instability in the market that may increase investment risks in the short term.
- Investor Attention: Due to the high volatility of the stock, investors may need to reassess their investment strategies to cope with potential price swings and market risks, thereby affecting the overall performance of their portfolios.
- Market Sentiment: The volatility of Hims & Hers stock may trigger changes in market sentiment, leading investors to develop varying perspectives on the company's future prospects, which could influence its market performance.
See More
Hims & Hers Stock Volatility Analysis
- Market Volatility: Hims & Hers (NYSE: HIMS) has recently emerged as one of the most volatile stocks in the market, reflecting investor uncertainty about its future performance, which could impact its short-term stock price.
- Lack of Investment Recommendations: The Motley Fool Stock Advisor analyst team has indicated that Hims & Hers is not among the current top 10 recommended stocks, suggesting a cautious market sentiment regarding its growth potential, which may lead investors to reassess its investment value.
- Historical Return Comparison: Compared to previously recommended stocks like Netflix and Nvidia, which yielded returns of 515,294% and 1,077,442% respectively, Hims & Hers has not demonstrated similar appeal, indicating a lack of confidence in the stock.
- Investor Community Engagement: The Motley Fool encourages investors to join its community to share insights, and while Hims & Hers has not made the recommendation list, it still maintains a degree of attention among investors, potentially influencing future market dynamics.
See More
Hims & Hers Health Faces Legal Investigation Over Securities Violations
- Legal Investigation Launched: The Schall Law Firm is investigating Hims & Hers Health for potential securities law violations, focusing on whether the company made false or misleading statements that could harm investors' interests.
- FDA Statement Impact: The FDA announced its intent to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, directly affecting Hims & Hers' market operations and potentially leading to stricter regulations.
- Increased Litigation Risk: Hims & Hers is also facing a lawsuit from Novo Nordisk seeking to bar the sale of compounded weight loss drugs, which will further escalate the company's legal risks and could impact its market share.
- Significant Stock Decline: Following these developments, Hims & Hers' shares fell by over 17.8% during afternoon trading on February 9, 2026, reflecting market concerns about the company's future prospects and potentially undermining investor confidence.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
FDA Moves to Lift Restrictions on Peptides, Boosting Hims & Hers Shares
- Stock Surge: Hims & Hers Health Inc. (HIMS) shares surged nearly 6% in Tuesday morning trading, primarily driven by the FDA's plan to lift restrictions on peptide drugs, reflecting market optimism about the company's growth prospects.
- Policy Shift: According to a report by The New York Times, the FDA is considering allowing compounding pharmacies to manufacture over a dozen injectable peptides that were previously banned due to safety risks, which will create new market opportunities for companies like HIMS.
- Market Impact: This policy reversal will end a 2023 ban on 14 peptides, meaning HIMS can re-enter this potentially lucrative market, thereby enhancing its competitiveness in the compounded medication sector.
- Industry Outlook: With the FDA's decision, HIMS is poised to expand its product line to meet the growing customer demand, further solidifying its market position in the health tech industry.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
